logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Late-line mCRC: bulk tied to poorer anti-EGFR outcomes

Metastatic bulk should be examined alongside molecular profiling in late-line mCRC.